Kiyokazu Yoshida

A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung Cancer

Kunihiko Kobayashi, Fumikazu Takeda, Satoshi Teramukai et al. · European Journal of Cancer · 1998 · 255 citations

Medicine, Oncology, Treatment Planning +1

Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer

Kiyoyuki Furuse, Kaoru Kubota, Masaaki Kawahara et al. · Oncology · 2009 · 83 citations

Medicine, Oncology, Pharmacology +15

Efficacy of a New 5-Fluorouracil Derivative, Bof-A2, in Advanced Non-Small Cell Lung Cancer a Multi-Center Phase Ii Study

Yushi Nakai, Kiyoyuki Furuse, Mitsuo Ohta et al. · Acta Oncologica · 1994 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer

Minoru Takada, Masahiro Fukuoka, Y Ariyoshi et al. · Cancer Chemotherapy and Pharmacology · 1992 · 12 citations

Medicine, Oncology, Pharmacology +14

The cytotoxicity of 5-fluorouracil is due to its incorporation into RNA not its inhibition of thymidylate synthase as evidenced by the use of a mouse cell mutant deficient in thymidylate synthase.

S Akazawa, R Kumai, Kiyokazu Yoshida et al. · PubMed · 1986 · 10 citations

Medicine, Molecular Biology, Oncology +10